[go: up one dir, main page]

MX2018010948A - INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS. - Google Patents

INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.

Info

Publication number
MX2018010948A
MX2018010948A MX2018010948A MX2018010948A MX2018010948A MX 2018010948 A MX2018010948 A MX 2018010948A MX 2018010948 A MX2018010948 A MX 2018010948A MX 2018010948 A MX2018010948 A MX 2018010948A MX 2018010948 A MX2018010948 A MX 2018010948A
Authority
MX
Mexico
Prior art keywords
tgfß1
immunoglobulins
binding
same
lrrc33
Prior art date
Application number
MX2018010948A
Other languages
English (en)
Inventor
J Carven Gregory
Schurpf Thomas
Datta Abhishek
Long Kimberly
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58503696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018010948(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MX2018010948A publication Critical patent/MX2018010948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen en la presente inmunoglobulinas, tal como anticuerpos, y porciones de enlace a antígeno de los mismos, que enlazan específicamente complejos de GARP-TGFß1, LTBP1-TGFß1, LTBP3-TGFß1 y/o LRRC33-TGFß1. La solicitud también proporciona métodos de uso de estas inmunoglobulinas para, por ejemplo, inhibir la actividad de TGFß1, y tratar sujetos que padecen de trastornos relacionados con TGFß1, tal como cáncer y fibrosis.
MX2018010948A 2016-03-11 2017-03-10 INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS. MX2018010948A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662307353P 2016-03-11 2016-03-11
US201762443615P 2017-01-06 2017-01-06
US201762452866P 2017-01-31 2017-01-31
PCT/US2017/021972 WO2017156500A1 (en) 2016-03-11 2017-03-10 Tgfb1-binding immunoglobulins and use thereof

Publications (1)

Publication Number Publication Date
MX2018010948A true MX2018010948A (es) 2019-06-20

Family

ID=58503696

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010948A MX2018010948A (es) 2016-03-11 2017-03-10 INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
MX2024005811A MX2024005811A (es) 2016-03-11 2018-09-10 Inmunoglobulinas de enlace a tgf?1 y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024005811A MX2024005811A (es) 2016-03-11 2018-09-10 Inmunoglobulinas de enlace a tgf?1 y usos de las mismas.

Country Status (19)

Country Link
US (2) US11643459B2 (es)
EP (2) EP4169942A1 (es)
JP (4) JP2019509737A (es)
KR (3) KR20230088508A (es)
CN (1) CN109071646A (es)
AU (2) AU2017230103A1 (es)
BR (1) BR112018068340A2 (es)
CA (1) CA3055555A1 (es)
DK (1) DK3365368T3 (es)
EA (1) EA201891909A1 (es)
ES (1) ES2951648T3 (es)
FI (1) FI3365368T3 (es)
HU (1) HUE062976T2 (es)
IL (2) IL307835A (es)
MX (2) MX2018010948A (es)
PL (1) PL3365368T3 (es)
PT (1) PT3365368T (es)
SG (1) SG11201807176XA (es)
WO (1) WO2017156500A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3365368T3 (fi) * 2016-03-11 2023-06-13 Scholar Rock Inc Tgf-beeta-1:tä sitovia immunoglobuliineja ja niiden käyttö
IL264161B2 (en) * 2016-07-14 2025-06-01 Scholar Rock Inc Tgfb antibodies, methods, and uses
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
JP2020512364A (ja) * 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ
ES2958587T3 (es) 2017-05-09 2024-02-12 Scholar Rock Inc Inhibidores de LRRC33 y uso de los mismos
EP3658583A1 (en) * 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
EP3755723A4 (en) 2018-02-23 2021-12-22 Chugai Seiyaku Kabushiki Kaisha CROSS SPECIES ANTI-LATENT TGF-BETA-1 ANTIBODIES AND METHOD OF USE
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
BR112021000353A2 (pt) 2018-07-11 2021-08-03 Scholar Rock, Inc. inibidores de tgfb1 de alta afinidade, isoforma-seletivos, e seus usos
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
CN113613725B (zh) * 2018-11-05 2025-09-23 路德维格癌症研究所有限公司 人源化和变体TGF-β1特异性抗体及其方法和用途
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
AU2020290119B2 (en) * 2019-06-10 2024-07-18 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PDL1 and TGFβ and use thereof
BR112022003412A2 (pt) * 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso
AU2021205440A1 (en) * 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
WO2021142427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. TGFβ INHIBITORS AND USE THEREOF
EP4126919A1 (en) * 2020-03-24 2023-02-08 Bio-Techne Corporation Methods of using a tgf beta knockout cell line and compositions resulting therefrom
TW202241955A (zh) * 2021-01-18 2022-11-01 大陸商上海濟煜醫藥科技有限公司 Ｇａｒｐ蛋白抗體及其應用
JP7280400B2 (ja) * 2021-02-26 2023-05-23 中外製薬株式会社 種交差性抗潜在型ＴＧＦ－β１抗体の使用
WO2022180764A1 (en) 2021-02-26 2022-09-01 Chugai Seiyaku Kabushiki Kaisha Uses of cross-species anti-latent tgf-beta 1 antibodies
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022206753A1 (zh) * 2021-03-29 2022-10-06 山东先声生物制药有限公司 GARP/TGFβ1抗体及其应用
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023192895A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
GB202219154D0 (en) * 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
WO2024149237A1 (zh) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
IL322242A (en) 2023-02-10 2025-09-01 Chugai Pharmaceutical Co Ltd Anti-latent TGF-BETA 1 antibodies and methods of use
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
CN120131938B (zh) * 2025-03-19 2025-12-23 广州奥奇生物技术有限公司 一种益生菌制剂的制备方法及其在改善睡眠中的应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2411374C (en) 2000-06-29 2012-10-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
GB0230202D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Ligand
US7803553B2 (en) * 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
AU2006213875B2 (en) 2005-02-08 2010-08-19 Genzyme Corporation Antibodies to TGFBETA
EA016038B1 (ru) * 2005-04-22 2012-01-30 Эли Лилли Энд Компани Антитело к tgf-бета и его применение
BR122020022640B1 (pt) 2007-03-22 2022-03-29 UCB Biopharma SRL Molécula de dna codificando proteínas de ligação a cd154, vetor, célula hospedeira e método de produção das referidas proteínas
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
US8889130B2 (en) 2011-02-08 2014-11-18 Abbvie Inc. Treatment of osteoarthritis and pain
JP6342325B2 (ja) 2011-05-25 2018-06-13 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 炎症性障害の治療のための抗ｋｉｒ抗体
DK2714735T3 (da) * 2011-06-03 2021-10-18 Xoma Technology Ltd Antistoffer, der er specifikke for TGF-beta
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
US20140286959A1 (en) 2011-11-08 2014-09-25 Pfizer Inc. Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
EP2822592B1 (en) * 2012-03-08 2018-08-15 Ludwig Institute for Cancer Research Limited Tgf- 1 specific antibodies and methods and uses thereof
SG10201704616SA (en) 2012-11-06 2017-07-28 Scholar Rock Inc Compositions and methods for modulating cell signaling
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP3816625B1 (en) 2013-05-06 2025-09-17 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
EA035550B1 (ru) * 2013-08-01 2020-07-06 Юниверсите Католик Де Лувэн АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ
US20170073406A1 (en) 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
KR102622280B1 (ko) 2014-06-26 2024-01-08 하이델베르크 이뮤노테라퓨틱스 게엠베하 항-hsv 항체의 국소 적용
US10822398B2 (en) 2014-11-18 2020-11-03 Institut Pasteur Polyclonal antibodies specific for serogroup x of N. meningitidis and uses thereof in diagnosis
CN107530423B (zh) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 用抗lap单克隆抗体治疗癌症
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
FI3365368T3 (fi) 2016-03-11 2023-06-13 Scholar Rock Inc Tgf-beeta-1:tä sitovia immunoglobuliineja ja niiden käyttö
IL264161B2 (en) 2016-07-14 2025-06-01 Scholar Rock Inc Tgfb antibodies, methods, and uses
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof

Also Published As

Publication number Publication date
FI3365368T3 (fi) 2023-06-13
KR20250011248A (ko) 2025-01-21
KR20180122397A (ko) 2018-11-12
BR112018068340A2 (pt) 2019-01-15
SG11201807176XA (en) 2018-09-27
AU2024202692A1 (en) 2024-05-30
US11643459B2 (en) 2023-05-09
MX2024005811A (es) 2024-05-28
PT3365368T (pt) 2023-08-17
EA201891909A1 (ru) 2019-02-28
WO2017156500A9 (en) 2018-02-22
JP2023108057A (ja) 2023-08-03
ES2951648T3 (es) 2023-10-24
DK3365368T3 (da) 2023-06-26
IL307835A (en) 2023-12-01
IL261442A (en) 2018-10-31
KR20230088508A (ko) 2023-06-19
US20230348583A1 (en) 2023-11-02
PL3365368T3 (pl) 2023-08-21
WO2017156500A1 (en) 2017-09-14
WO2017156500A8 (en) 2018-01-25
JP7794630B2 (ja) 2026-01-06
JP2022028680A (ja) 2022-02-16
CA3055555A1 (en) 2017-09-14
JP2022031403A (ja) 2022-02-18
EP3365368A1 (en) 2018-08-29
HUE062976T2 (hu) 2023-12-28
EP4169942A1 (en) 2023-04-26
AU2017230103A1 (en) 2018-09-06
JP2019509737A (ja) 2019-04-11
CN109071646A (zh) 2018-12-21
US20190071493A1 (en) 2019-03-07
EP3365368B1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
CY1125327T1 (el) Anti-pd-1 αντισωματα και συνθεσεις
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
MX2017006301A (es) Conjugados de anticuerpo- farmaco.
MX2018016344A (es) Miembros de union lag-3.
HK1255039A1 (zh) 对pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
ECSP18005520A (es) Anticuerpos de factor xi y métodos de uso
EA201892581A1 (ru) Варианты комбинированной терапии ингибиторами hdac и ингибиторами pd-l1
BR112015021115A2 (pt) agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes
ECSP21090414A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX2020006585A (es) Anticuerpos que se unen a ctla-4 y usos de los mismos.
DOP2021000161A (es) INHIBIDORES ESPECÍFICOS DEL COMPLEJO DE LTBP DE TGFß Y USOS DE LOS MISMOS
NI201000028A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
MX391935B (es) Anticuerpos inhibidores de via del factor tisular y usos de los mismos.
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
MX2019012428A (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
EA201891299A1 (ru) Терапевтические антитела к cd9
MX2024005841A (es) Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.